Cochrane · systematic review · CD007845
Momordica charantia for type 2 diabetes mellitus
Ooi, CP, Yassin, Z, Hamid, TA · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
Metabolic and Endocrine DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
2
No studies
4
Included studies
NR
No studies 4 · 66.7%Ungraded 0 · 0%Very low 1 · 16.7%Low 1 · 16.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Momordica charantia for type 2 diabetes mellitus
Population: Patients with type 2 diabetes mellitus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death from any cause | no estimate extracted | NR | No studies |
Morbidity | no estimate extracted | NR | No studies |
Adverse effects ( | no estimate extracted | 4 studies · 479 participants | Low |
Health‐related quality of life | no estimate extracted | NR | No studies |
Costs | no estimate extracted | NR | No studies |
Change in HbA1c from baseline to endpoint ( | no estimate extracted | 1 study · 40 participants | Very low Downgraded: imprecision |